SCHEMBL10260244

SCHEMBL10260244

CO[C@H]1C[C@@H](O)[C@H](O)[C@@H](CO)O1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PYGB P11216 1/20 0.38
LGALS8 O00214 4/20 0.37
LGALS3 P17931 3/20 0.37
LGALS4 P56470 1/20 0.37
STAT3 P40763 4/20 0.37
SLC5A1 P13866 1/20 0.37
ATP1A1 P05023 1/20 0.35
ATP1B1 P05026 1/20 0.35
ATP1A3 P13637 1/20 0.35
ATP1B2 P14415 1/20 0.35
ATP1A2 P50993 1/20 0.35
ATP1B3 P54709 1/20 0.35
FXYD2 P54710 1/20 0.35
ATP1A4 Q13733 1/20 0.35
LGALS1 P09382 2/20 0.34
LGALS9 O00182 1/20 0.34
MGAM O43451 2/20 0.34
SI P14410 2/20 0.34
OGA O60502 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8658239 1.00 PYGB (0.38) PYGBLGALS8LGALS3LGALS4STAT3
SCHEMBL10776061 1.00 PYGB (0.38) PYGBLGALS8LGALS3LGALS4STAT3
SCHEMBL14502564 1.00 PYGB (0.38) PYGBLGALS8LGALS3LGALS4STAT3
SCHEMBL25083708 1.00 PYGB (0.38) PYGBLGALS8LGALS3LGALS4STAT3
SCHEMBL8658242 1.00 PYGB (0.38) PYGBLGALS8LGALS3LGALS4STAT3
SCHEMBL23240738 1.00 PYGB (0.38) PYGBLGALS8LGALS3LGALS4STAT3
SCHEMBL13862964 1.00 PYGB (0.38) PYGBLGALS8LGALS3LGALS4STAT3
SCHEMBL23059621 1.00 PYGB (0.38) PYGBLGALS8LGALS3LGALS4STAT3
SCHEMBL12964266 1.00 PYGB (0.38) PYGBLGALS8LGALS3LGALS4STAT3
SCHEMBL14502565 1.00 PYGB (0.38) PYGBLGALS8LGALS3LGALS4STAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019195430-A1 STREPTOCOCCUS MUTANS GLUCOSYL TRANSFERASE INHIBITORS FOR DENTAL CARIES THERAPY UAB RESEARCH FOUNDATION (US) 2019-10-10 WO disclosed
EP-1637539-B1 PYRAZOLE DERIVATIVE, DRUG COMPOSITION CONTAINING THE SAME AND PRODUCTION INTERMEDIATE THEREFOR KISSEI PHARMACEUTICAL (JP) 2012-01-18 EP disclosed
US-7888487-B2 Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-02-15 US disclosed
US-7888487-B2 Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-02-15 US disclosed
US-20100029919-A1 PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE IN PRODUCING THE SAME KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-02-04 US disclosed
US-20100029919-A1 PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE IN PRODUCING THE SAME KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-02-04 US disclosed
US-7576064-B2 Pyrazole derivative, drug composition containing the same and production intermediate therefor KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-08-18 US disclosed
US-7576064-B2 Pyrazole derivative, drug composition containing the same and production intermediate therefor KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-08-18 US disclosed
US-7576063-B2 Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-08-18 US disclosed
US-7576063-B2 Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-08-18 US disclosed
US-20070060531-A1 Pyrazole derivative, drug composition containing the same and production intermediate therefor KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-03-15 US disclosed
US-20070060531-A1 Pyrazole derivative, drug composition containing the same and production intermediate therefor KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029919-A1 PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE IN PRODUCING THE SAME SLC2A3, SLC2A1, SLC5A1 PYGB 1380/4885LGALS8 838/4885LGALS3 505/4885
US-20070060531-A1 Pyrazole derivative, drug composition containing the same and production intermediate therefor SLC5A1, SLC5A2, SLC2A1 PYGB 1507/4885LGALS8 445/4885LGALS3 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.